Mefford I N, Roth K A, Gilberg M, Barchas J D
Eur J Pharmacol. 1981 Mar 26;70(3):345-53. doi: 10.1016/0014-2999(81)90168-0.
SKF 64139, a potent inhibitor of adrenal and brain phenylethanolamine-N-methyltransferase (PNMT), was found to have effects on catecholamines, serotonin and their metabolites in rat brain which suggest it may act as a potent inhibitor of monoamine oxidase (MAO) 'in vivo' after acute administration. Evidence of this was obtained by observing the concurrent elevation of serotonin and depletion of its major metabolite 5-hydroxyindoleacetic acid (5-HIAA), as well as depletion of the dopamine metabolites homovanillic acid and 3,4-dihydroxyphenyl-acetic acid (DOPAC) following acute administration. Additional evidence was obtained by antagonism of the increase in acid metabolites and depletion of amines following treatment with reserpine. Using the depletion of brain DOPAC as an index of MAO activity, an ED50 of 3-4 mg/kg was found for SKF 64139 as an "in vivo' MAO inhibitor.
SKF 64139是肾上腺和脑苯乙醇胺-N-甲基转移酶(PNMT)的强效抑制剂,研究发现它对大鼠脑中的儿茶酚胺、5-羟色胺及其代谢产物有影响,这表明在急性给药后,它可能在“体内”作为单胺氧化酶(MAO)的强效抑制剂发挥作用。急性给药后,5-羟色胺及其主要代谢产物5-羟吲哚乙酸(5-HIAA)同时升高,以及多巴胺代谢产物高香草酸和3,4-二羟基苯乙酸(DOPAC)减少,由此获得了相关证据。在用利血平处理后,通过对抗酸性代谢产物增加和胺类减少,获得了更多证据。以脑DOPAC减少作为MAO活性指标,发现SKF 64139作为“体内”MAO抑制剂的半数有效剂量(ED50)为3 - 4毫克/千克。